Significantly more A+M - treated patients achieved HbA1c < 7 % ( 47.1-59 .5 % vs. 20.2-34 .3 % with monotherapy ) , significantly fewer required hyperglycaemic rescue ( 2.6-12 .3 % vs. 10.8-22 .9 % with monotherapy ) .